A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-09-14
Target enrollment:
Participant gender:
Summary
This is a first-in-human, multicenter, Phase 1, open-label, dose-escalation study designed to
evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),
immunogenicity, and preliminary efficacy of KGX101, a tumor-activated interleukin 12 prodrug,
as monotherapy in patients with advanced or metastatic solid tumors.